Accueil › Cancer du poumon non à petites cellules › Minnesota › Saint Paul
Essais cliniques pour Cancer du poumon non à petites cellules à Saint Paul, MN
19 études pour Cancer du poumon non à petites cellules recherchent des participants dans et autour de Saint Paul (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Recrutement en coursPhase 3
- United Hospital, Saint Paul
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- Regions Hospital, Saint Paul
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 2
- Health Partners Cancer Center at Regions Hospital, Saint Paul
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- Regions Hospital, Saint Paul
- United Hospital, Saint Paul
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Recrutement en coursPhase 3
- Allina Health Cancer Institute - United Hospital, Saint Paul
- Minnesota Oncology Hematology, P.A., Maplewood · à 5 mi
- Minnesota Oncology Hematology, PA, Woodbury · à 7 mi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Allina Health Cancer Institute - United Hospital, Saint Paul
- Minnesota Oncology Hematology, P.A., Maplewood · à 5 mi
- Minnesota Oncology Hematology, P.A., Woodbury · à 7 mi
- et 1 autres
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Recrutement en coursPhase 3
- Regions Hospital, Saint Paul
- M Health Fairview St. John's Hospital, Maplewood · à 5 mi
- Minnesota Oncology Hematology PA, Maplewood · à 5 mi
- et 1 autres
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Recrutement en coursPhase 2
- Regions Hospital, Saint Paul
- United Hospital, Saint Paul
- Minnesota Oncology Hematology PA-Maplewood, Maplewood · à 5 mi
- et 3 autres
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Recrutement en coursPhase 3
- Clinical Study Site, Saint Paul
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- HealthPartners Cancer Research Center, Saint Paul
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- Research Site, Saint Paul
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recrutement en coursPhase 1/2
- USOR Minnesota Oncology Hematology, Maplewood · à 5 mi
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recrutement en coursPhase 1/2
- Health Partners Cancer Center at Regions Hospital, Saint Paul
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Recrutement en coursPhase 1/2
- HealthPartners Cancer Center at Regions Hospital, Saint Paul
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recrutement en coursPhase 1
- Allina Health Cancer Institute - United Hospital, Saint Paul
- Allina Health Cancer Institute, Saint Paul
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Regions Hospital, Saint Paul
- United Hospital, Saint Paul
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- Regions Hospital, Saint Paul
- United Hospital, Saint Paul
- Minnesota Oncology Hematology PA-Woodbury, Woodbury · à 7 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Recrutement en coursÉtude observationnelle
- Regions Hospital, Saint Paul
- United Hospital, Saint Paul
- Minnesota Oncology Hematology PA-Maplewood, Maplewood · à 5 mi
- et 3 autres
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Research Site 121, Saint Paul
Essais pour Cancer du poumon non à petites cellules dans d'autres villes
- Houston, TX145 études
- New York City, NY121 études
- Arlington, VA104 études
- Nashville, TN97 études
- Boston, MA90 études
- Los Angeles, CA87 études
- St. Louis, MO73 études
- Chicago, IL61 études
- Baltimore, MD60 études
- San Antonio, TX59 études
- Columbus, OH57 études
- Washington, DC55 études
Autres études à Saint Paul
- Cancer de la prostate13 études
- Cancer du poumon13 études
- Cancer du sein12 études
- Cancer colorectal9 études
- Cancer de l'ovaire8 études
- Cancer métastatique7 études
- Cancer du rein (carcinome à cellules rénales)7 études
- Cancer de l'endomètre6 études
- Cancer de la vessie6 études
- Mélanome6 études
- Carcinome épidermoïde de la tête et du cou6 études
- Leucémie aiguë myéloïde6 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.